German medtech startup PreciPoint raises €10M to digitise microscopy and laboratory workflows

Bayern-based PreciPoint, a company that specialises in developing, producing and marketing digitisation solutions and photonics systems, announced on Wednesday that it has raised €10M in a Series A round of funding.

PreciPoint says it will use the funds to expand the international commercialisation of its first IVD medical product, as well as expand its services in the US and further develop its technological advancements.

Investors in this round

The investment came from existing investors, including bm-t beteiligungsmanagement thüringen (bm|t), and a new family office. 

Stefan Jahn, Senior Investment Manager at bm|t, says, “Since our seed investment in 2019, the team around the two co-founders and managing directors Nicolas Weiss and Dominik Gerber has made enormous progress. Renowned distribution partners could be acquired, new products could be developed and successfully placed on the market. At the same time, the prerequisites were created to quickly scale the company. We firmly believe that PreciPoint, as an ISO13485 certified medical device company, will be able to successfully position its product portfolio on the European and American markets.”

Digitising microscopy and laboratory workflows

Founded in 2018, PreciPoint is a medtech startup that produces solutions for the digitisation of microscopy and laboratory processes for applications in medicine, research, and education.

The company’s available products are the M8, O8 as well as FRITZ, a microscopy slide scanner. These are fully motorised transmitted light microscopes, which produce high-resolution images and can be handled remotely.

The company also provides software tools for processing, analysing, and visualising data, as well as the virtual microscopy platform PreciCloud for storing and sharing images.

PreciPoint reports that it will launch the iO:M8 ROSE solution to customers in 2022. This solution is for the digitisation of intraoperative assessments during cancer surgeries. Using traditional microscopes, these tests were constrained by space and time. The solutions from PreciPoint will allow new working methods, resulting in cost reductions and improved patient care.

The company is concentrating on the development of high-speed product solutions and label-free diagnostic technologies that allow samples to be examined without the need for pricy and time-consuming pre-treatment.